 Aptose Biosciences Inc. Aptose or the Company NASDAQ: APTO, TSX: APS, a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that new clinical data on CG-806, its oral, first-in-class FLT3BTK cluster selective kinase inhibitor, was presented in a poster presentation today at the 25th Congress of the European Hematology Association, EHA25 Virtual Congress. Early Clinical Findings from a Phase 1 ab Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLLSLL or Non-Hodgkins Lymphomas EHA2020 Abstract EP711 reviewed CG-806 data for eight patients as of the data cut-off date on May 5, 2020 with relapsed or refractory chronic lymphocytic leukemia CLL small lymphocytic lymphoma SLL or non-Hodgkins lymphoma in the first in-human Phase 1 ab, open-label, single arm, multicenter dose-escalation clinical study. 